None listed
Conditions
Brief summary
The study will investigate a new PET radiotracer PI-2620 to see if it can visual the tau protein which is observed in the brains of patients with progressive supranuclear palsy (PSP). The tau protein builds up in certain brain areas in patients with PSP, such as the basal ganglia. We hypothesise that PI-2620 will show high levels of uptake in the basal ganglia, indicating the presence of tau. Patients will undergo a single PET scan, whereby we inject a small amount of the radiotracer. The patient will then be scanned for 60 minutes. The resulting image will then show whether or not the radiotracer binds in the basal ganglia (indicating tau accumulation). The amount of tau in the basal ganglia can be measured from these images and we will then establish whether the levels of tau increase with increasing severity of PSP symptoms. If successful this radiotracer could be used in the future to help diagnose PSP.
Interventions
New PET radiotracer, PI-2620, 185MBq, intravenous. Single administration by certified nuclear medicine technologist. Potential new diagnostic tool. Patients will undergo a single PET scan (duration 60 minutes), the scan will start concurrently with injection of the radiotracer.
Sponsors
Alfred Health
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Diagnosis
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
40 Years to 86 Years
Healthy volunteers
No
Inclusion criteria
Diagnosed with probable Progressive Supranuclear Palsy (MDS criteria) Not pregnant/breastfeeding Stable PSP medications for previous 30 days Able to provide written informed consent
Exclusion criteria
1. Unstable medical condition that could impact participant safety or completion of study procedures 2. Subject having received an investigational treatment targeting tau or amyloid within 3 months of imaging visit.
Outcome results
None listed